$40.70
-1.64%Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development.
Quality against peers; 50 is the peer median.
Showing the last 4 periods. Pro adds the full annual and quarterly history and 20+ more metrics to chart.
The latest fiscal year and quarter, each against the same period a year earlier, from SEC filings.
From the notes to the annual report for fiscal 2025, ending December.
The next report, and the record against analysts' estimates.
Fundamentals: fiscal year to Dec 2025. This company files annual reports only.
IM industry median · SM sector median: the typical company the value is compared with. The /100 is its score against those peers.
A reverse discounted-cash-flow model: the yearly growth in free cash flow over the next ten years that today's enterprise value pays for.
The price assumes less growth than the company has lately delivered.
The same assumptions for every company, so the figure compares expectations rather than valuing any one: a 9% discount rate, then 2.5% growth for ever after year 10, from the latest trailing free cash flow. Not shown for banks and insurers, or without positive free cash flow.
The companies closest in size in Drug Manufacturers - General (filled from its sector when there are few), with the median and rank across all 21 in the industry.